Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) (Trelegy Ellipta) significantly increased trough forced expiratory volume in 1 second (FEV₁) at 24 weeks compared to other triple therapy options, except UMEC + FF/VI, in adults aged ≥40 years with moderate to very severe COPD.
• FF/UMEC/VI showed statistically significant reductions in the annualized rate of combined moderate or severe exacerbations versus budesonide/glycopyrronium bromide/formoterol fumarate (BUD/GLY/FOR) and UMEC + FF/VI, as well as improvements in St George’s Respiratory Questionnaire (SGRQ) scores and reductions in rescue medication use over 24 weeks.
• BUD/GLY/FOR and BGF MDI demonstrated comparable efficacy to FF/UMEC/VI in improving lung function, reducing exacerbation rates, and enhancing health-related quality of life at both 24 and 52 weeks.
• The safety profile of FF/UMEC/VI was not detailed in the reviewed studies.
• BUD/GLY/FOR and budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) were found to have a safety and tolerability profile comparable to other inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) fixed-dose and open combination therapies, with no statistically significant differences in safety outcomes for BGF MDI.
• There is no population types or subgroups information available in the reviewed studies.